

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT	DISEASE Unknown primary adenocarcinoma	PHYSICIAN	ORDERING PHYSICIAN Yeh, Yi-Chen	SPECIMEN	SPECIMEN ID CJK 3/19/1949
	NAME Kan, Chin-Jung		MEDICAL FACILITY Taipei Veterans General Hospital		SPECIMEN TYPE Blood
	DATE OF BIRTH 19 March 1949		ADDITIONAL RECIPIENT None		DATE OF COLLECTION 21 February 2023
	SEX Male		MEDICAL FACILITY ID 205872		SPECIMEN RECEIVED 23 February 2023
	MEDICAL RECORD # 49181820		PATHOLOGIST Not Provided		

Biomarker Findings

Blood Tumor Mutational Burden - 0 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction Not Detected

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KRAS G12D
ASXL1 S485fs*4
DNMT3A V716I
TP53 R248Q, H179L

Report Highlights

- Evidence-matched clinical trial options based on this patient's genomic findings: (p. [9](#))
- Variants that may represent clonal hematopoiesis and may originate from non-tumor sources: **ASXL1** S485fs*4 (p. [7](#)), **DNMT3A** V716I (p. [7](#))

BIOMARKER FINDINGS

Blood Tumor Mutational Burden -
 0 Muts/Mb

Microsatellite status -
 MSI-High Not Detected

Tumor Fraction -
 Elevated Tumor Fraction Not Detected

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. See Biomarker Findings section

MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).

Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Biomarker Findings section).

GENOMIC FINDINGS

KRAS - G12D 0.21%

10 Trials see p. [9](#)

VAF%

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)

None

THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)

None

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

ASXL1 - S485fs*4 p. [7](#) **DNMT3A** - V716I p. [7](#)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

ASXL1 - S485fs*4 **p. [7](#)** **TP53 - R248Q, H179L** **p. [8](#)**
DNMT3A - V716I **p. [7](#)**

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC, ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MEN1, MLH1, MSH2, MSH6, MUTYH, NF1, NF2, PALB2, PMS2, POLE, PTEN, RAD51C, RAD51D, RB1, RET, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.


Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01



HISTORIC PATIENT FINDINGS

ORD-1573456-01
VAF%

Blood Tumor Mutational Burden

0 Muts/Mb

Microsatellite status

MSI-High Not Detected

Tumor Fraction

Elevated Tumor Fraction Not Detected

KRAS	● G12D	0.21%
ASXL1	● S485fs*4	1.4%
DNMT3A	● V716I	0.88%
TP53	● R248Q	0.25%
	● H179L	0.10%

IMPORTANT NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. Variants reported for prior time points reflect reporting practices at the time of the historical test(s). Changes in variant reporting nomenclature, classification, or handling may result in the appearance of discrepancies across time points. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable or reportable variants may become VUS.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of $\geq 5\%$, and bTMB is calculated based on variants with an allele frequency of $\geq 0.5\%$.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Please note that other aspects of this table may have changed from the previous version to reflect the most up-to-date reporting information.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

BIOMARKER FINDINGS

BIOMARKER

Blood Tumor Mutational Burden

RESULT

0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1¹⁻³, anti-PD-1³⁻⁴, anti-PD-1/CTLA4 therapies⁵⁻⁶, anti-PD-L1/CTLA4 therapies⁷⁻¹⁰. A Phase 2 multi-solid-tumor trial showed that bTMB ≥ 16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor⁵. In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb^{1,8-10}. In head and neck squamous cell

carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥ 16 Muts/Mb (approximate equivalency ≥ 8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor¹¹. In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥ 28 Muts/Mb (approximate equivalency ≥ 14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor⁷.

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis¹², as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high-TMB samples each), but not BRAF (10.3%) or KRAS (9.4%)¹³. Although some studies have reported a lack of association between smoking and increased TMB in NSCLC^{12,14}, several other large studies did find a strong link¹⁵⁻¹⁸. In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations¹⁹⁻²⁰ and with

microsatellite instability (MSI)²⁰, which in turn has been reported to correlate with better prognosis²¹⁻²⁸. Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma²⁹⁻³² and bladder cancer³³, it is also linked with improved prognosis in patients with these tumor types³⁰.

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma³⁴⁻³⁵ and cigarette smoke in lung cancer³⁶⁻³⁷, treatment with temozolomide-based chemotherapy in glioma³⁸⁻³⁹, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes^{19,30,40-42}, and microsatellite instability (MSI)^{19,30,42}. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents¹⁻²⁴. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT

Elevated Tumor Fraction Not Detected

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not

be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management⁴³⁻⁴⁸.

FREQUENCY & PROGNOSIS

Detectable ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)⁴⁹. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer⁵⁰, Ewing sarcoma and osteosarcoma⁵¹, prostate cancer⁴⁶, breast cancer⁵², leiomyosarcoma⁵³, esophageal cancer⁵⁴, colorectal

cancer⁵⁵, and gastrointestinal cancer⁵⁶.

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content⁵⁷, the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy⁵⁸⁻⁵⁹.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

GENOMIC FINDINGS

GENE

KRAS

ALTERATION

G12D

TRANSCRIPT ID

NM_004985.3

CODING SEQUENCE EFFECT

35G>A

VARIANT CHROMOSOMAL POSITION

chr12:25398284

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib⁶⁰⁻⁶⁵. While clinical responses have been reported for patients with KRAS-mutated ovarian⁶⁶⁻⁶⁹, cervical small cell neuroendocrine⁷⁰, or uterine cancer⁶⁸ treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS-altered tumors including KRAS-mutated CRC⁷¹⁻⁷⁴, pancreatic cancer⁷⁵⁻⁷⁷, and NSCLC^{72,78-79}. A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS-mutated (2/2 SDs) or KRAS-amplified (1/1 SD) cancer⁸⁰. Clinical responses have been reported for combination treatment strategies

including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS-mutated ovarian cancer⁸¹⁻⁸³ and KRAS-mutated endometrioid adenocarcinoma⁸⁴. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NSCLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma⁸⁵. Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS-mutated low-grade serous ovarian cancer and 12% (2/17) for patients with KRAS-mutated non-small cell lung cancer (NSCLC) in a Phase 1 study⁸⁶⁻⁸⁷. Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors⁸⁸⁻⁸⁹. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations⁹⁰. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer⁹¹. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors⁹²⁻⁹³. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations⁹⁴⁻⁹⁵.

FREQUENCY & PROGNOSIS

KRAS mutations have been observed in 18% of tumor samples analyzed in the COSMIC database, including 53% of pancreatic, 45% of peritoneal, 32% of colorectal, 21% of small intestinal, 18% of biliary tract, and 15% of lung tumors (Mar 2022)⁹⁶. Mutations in KRAS have been reported in 32-54% of colorectal cancer cases, with the G12C, G12V, and G13D mutations specifically identified in 7-11%, 26-32%, and 16-24% of cases, respectively⁹⁷⁻¹⁰². Additionally, an activating KRAS mutation has been reported in more than 80% of pancreatic adenocarcinomas, with the majority of mutations found at codon 12¹⁰³⁻¹⁰⁶. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma¹⁰⁴. One study found that KRAS mutations were correlated with shorter PFS and OS in cancer of unknown primary (CUP) tumors¹⁰⁷.

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation^{61,108}. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic^{61,109-131}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

GENOMIC FINDINGS

GENE

ASXL1

ALTERATION

S485fs*4

TRANSCRIPT ID

NM_015338.5

CODING SEQUENCE EFFECT

1451_1452insAATTCCCAGTTGA

VARIANT CHROMOSOMAL POSITION

chr20:31021439

FREQUENCY & PROGNOSIS

ASXL1 alterations occur infrequently across various solid tumor types¹³² and are not known to act as drivers in any specific solid cancer type¹³³. Published data investigating the prognostic implications of ASXL1 alterations in solid tumors are limited (PubMed, May 2022). In the context of clonal hematopoiesis, ASXL1 mutations are significantly enriched in current or former smokers¹³⁴.

FINDING SUMMARY

ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors¹³⁵⁻¹³⁷. Alterations such as seen here may disrupt ASXL1 function or expression¹³⁸⁻¹⁴⁰.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion¹⁴¹⁻¹⁴⁶. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy¹⁴¹⁻¹⁴². Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease¹⁴⁷. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{145,148-149}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in ASXL1.

GENE

DNMT3A

ALTERATION

V716I

TRANSCRIPT ID

NM_022552.3

CODING SEQUENCE EFFECT

2146G>A

VARIANT CHROMOSOMAL POSITION

chr2:25463536

relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, COSMIC, PubMed, Feb 2023)^{96,150-151}. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2023).

FINDING SUMMARY

The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation¹⁵²⁻¹⁵³. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor¹⁵⁴⁻¹⁵⁹. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion¹⁴¹⁻¹⁴⁶. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy¹⁴¹⁻¹⁴². Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease¹⁴⁷. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{145,148-149}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS

DNMT3A alterations have been reported at

ORDERED TEST # ORD-1573456-01

GENOMIC FINDINGS

GENE

TP53

ALTERATION

R248Q, H179L

TRANSCRIPT ID

NM_000546.4, NM_000546.4

CODING SEQUENCE EFFECT

743G>A, 536A>T

VARIANT CHROMOSOMAL POSITION

chr17:7577538, chr17:7578394

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib¹⁶⁰⁻¹⁶³ or p53 gene therapy such as SGT-53¹⁶⁴⁻¹⁶⁸. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype¹⁶⁹. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer¹⁷⁰. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with TP53-mutated ovarian cancer¹⁷¹. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone⁸¹. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel¹⁷². A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations¹⁷³. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal

cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring¹⁷⁴. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage¹⁶⁸. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR¹⁷⁵. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)¹⁷⁶.

FREQUENCY & PROGNOSIS

Pan-cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%)¹⁷⁷. TP53 loss of heterozygosity (LOH) is frequently seen in tumors and often occurs when one copy of TP53 harbors a mutation; in some tumors, LOH is correlated with progression¹⁷⁸⁻¹⁸¹. While the prognostic significance of TP53 alteration or dysregulation varies according to tumor type, studies have shown an association with poor prognosis for patients with breast cancer¹⁸²⁻¹⁸⁴, endometrial cancer¹⁸⁵⁻¹⁸⁶, HNSCC¹⁸⁷⁻¹⁸⁹, or urothelial cancer¹⁹⁰⁻¹⁹¹. In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD-L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD-1 inhibitors pembrolizumab and nivolumab in this study¹⁹². TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of

CRC¹⁹³.

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers¹⁹⁴. Alterations such as seen here may disrupt TP53 function or expression¹⁹⁵⁻¹⁹⁹.

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2022)²⁰⁰. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers²⁰¹⁻²⁰³, including sarcomas²⁰⁴⁻²⁰⁵. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000²⁰⁶ to 1:20,000²⁰⁵. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30²⁰⁷. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion¹⁴¹⁻¹⁴⁶. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy¹⁴¹⁻¹⁴². Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease¹⁴⁷. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH^{145,148-149}. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

CLINICAL TRIALS

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or

research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or

in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE

KRAS

ALTERATION

G12D

RATIONALE

KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited

clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors.

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT04985604

PHASE 1/2

DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors

TARGETS
BRAF, MEK

LOCATIONS: Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado

NCT03284502

PHASE 1

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

TARGETS
MEK, RAFs, NRAS

LOCATIONS: Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04892017

PHASE 1/2

A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.

TARGETS
ULK1, ULK2, MEK

LOCATIONS: Massachusetts, Texas, Pennsylvania

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

CLINICAL TRIALS
NCT03905148
PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
 RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas

NCT05159245
PHASE 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

TARGETS
 BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD-L1, MEK, CDK4, CDK6

LOCATIONS: Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)

NCT04817956
PHASE 2

Improving Public Cancer Care by Implementing Precision Medicine in Norway

TARGETS
 PD-L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K-alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL

LOCATIONS: Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)

NCT04551521
PHASE 2

CRAFT: The NCT-PMO-1602 Phase II Trial

TARGETS
 PD-L1, AKTs, MEK, BRAF, ALK, RET, ERBB2

LOCATIONS: Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)

NCT04720976
PHASE 1/2

JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

TARGETS
 MEK, SHP2, PD-1, EGFR, KRAS

LOCATIONS: Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

 Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

CREBBP
 G255R

PIK3C2B
 H1145L

PTPRO
 T805M

TEK
 P704S

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

APPENDIX

Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 Exons 4-9	ACVR1B	AKT1 Exon 3	AKT2	AKT3	ALK Exons 20-29, Introns 18, 19	ALOX12B	AMER1 (FAM123B or WTX)	APC
AR	ARAF Exons 4, 5, 7, 11, 13, 15, 16	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BCR* Introns 8, 13, 14	BRAF Exons 11-18, Introns 7-10	BRCA1 Introns 2, 7, 8, 12, 16, 19, 20	BRCA2 Intron 2	BRD4	BRIP1	BTG1
BTG2	BTK Exons 2, 15	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD70	CD74* Introns 6-8	CD79A	CD79B	CD274 (PD-L1)	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1 Exon 3	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2 Exons 5, 17, 18	DIS3	DNMT3A	DOT1L	EED	EGFR Introns 7, 15, 24-27	EMSY (C11orf30)	EP300	EPHA3
EPHB1	EPHB4	ERBB2	ERBB3 Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25	ERBB4	ERCC4	ERG	ERRF1	ESR1 Exons 4-8
ETV4* Intron 8	ETV5* Introns 6, 7	ETV6* Introns 5, 6	EWSR1* Introns 7-13	EZH2 Exons 4, 16, 17, 18	EZR* Introns 9-11	FANCA	FANCC	FANCG
FANCL	FAS	FBXW7	FGF10	FGF12	FGF14	FGF19	FGF23	FGF3
FGF4	FGF6	FGFR1 Introns 1, 5, Intron 17	FGFR2 Intron 1, Intron 17	FGFR3 Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17	FGFR4	FH	FLCN	FLT1
FLT3 Exons 14, 15, 20	FOXL2	FUBP1	GABRA6	GATA3	GATA4	GATA6	GID4 (C17orf39)	GNA11 Exons 4, 5
GNA13	GNAQ Exons 4, 5	GNAS Exons 1, 8	GRM3	GSK3B	H3-3A (H3F3A)	HDAC1	HGF	HNFI1A
HRAS Exons 2, 3	HSD3B1	ID3	IDH1 Exon 4	IDH2 Exon 4	IGF1R	IKBKE	IKZF1	INPP4B
IRF2	IRF4	IRS2	JAK1	JAK2 Exon 14	JAK3 Exons 5, 11, 12, 13, 15, 16	JUN	KDM5A	KDM5C
KDM6A	KDR	KEAP1	KEL	KIT Exons 8, 9, 11, 12, 13, 17, Intron 16	KLHL6	KMT2A (MLL) Introns 6, 8-11, Intron 7	KMT2D (MLL2)	KRAS

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1573456-01

APPENDIX

Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

LTK	LYN	MAF	MAP2K1 (MEK1) Exons 2, 3	MAP2K2 (MEK2) Exons 2-4, 6, 7	MAP2K4	MAP3K1	MAP3K13	MAPK1
MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MERTK	MET	MITF
MKNK1	MLH1	MPL Exon 10	MRE11 (MRE11A)	MSH2 Intron 5	MSH3	MSH6	MST1R	MTAP
MTOR Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56	MUTYH	MYB* Intron 14	MYC Intron 1	MYCL (MYCL1)	MYCN	MYD88 Exon 4	NBN	NF1
NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2 Intron 26	NOTCH3	NPM1 Exons 4-6, 8, 10	NRAS Exons 2, 3
NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)	NT5C2	NTRK1 Exons 14, 15, Introns 8-11	NTRK2 Intron 12	NTRK3 Exons 16, 17	NUTM1* Intron 1	P2RY8	PALB2
PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA Exons 12, 18, Introns 7, 9, 11	PDGFRB Exons 12-21, 23
PDK1	PIK3C2B	PIK3C2G	PIK3CA Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)	PIK3CB	PIK3R1	PIM1	PMS2	POLD1
POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PRKN (PARK2)	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1 Exons 3, 4, 6, 7, 10, 14, 15, 17, Introns 4-8	RARA Intron 2	RB1	RBM10	REL	RET Introns 7, 8, Exons 11, 13-16, Introns 9-11
RICTOR	RNF43	ROS1 Exons 31, 36-38, 40, Introns 31-35	RPTOR	RSP02* Intron 1	SDC4* Intron 2	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SLC34A2* Intron 4	SMAD2	SMAD4	SMARCA4	SMARCB1
SMO	SNCAIP	SOCS1	SOX2	SOX9	SPEN	SPOP	SRC	STAG2
STAT3	STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)	TERC* ncRNA	TERT* Promoter
TET2	TGFBR2	TIPARP	TMPRSS2* Introns 1-3	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2
TYRO3	U2AF1	VEGFA	VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status
 Blood Tumor Mutational Burden (bTMB)
 Tumor Fraction

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

APPENDIX

About FoundationOne® Liquid CDx

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Ciplastraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.



ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted

cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of $\geq 5\%$, and bTMB is calculated based on variants with an allele frequency of $\geq 0.5\%$.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*,

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

APPENDIX

About FoundationOne® Liquid CDx

KMT2D (MLL2), MPL, MYD88, SF3B1, TET2, TP53, and U2AF1.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2, and VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2, and U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of

disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

APPENDIX

About FoundationOne®Liquid CDx

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.6.0

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1573456-01

APPENDIX **References**

1. Gandara DR, et al. *Nat. Med.* (2018) PMID: 30082870
2. Wang Z, et al. *JAMA Oncol* (2019) PMID: 30816954
3. Sturgill EG, et al. *Oncologist* (2022) PMID: 35274716
4. Aggarwal C, et al. *Clin. Cancer Res.* (2020) PMID: 32102950
5. Schenker et al., 2022; AACR Abstract CT022
6. Saori et al., 2021; ESMO Abstract 80P
7. Chen EX, et al. *JAMA Oncol* (2020) PMID: 32379280
8. Rizvi NA, et al. *JAMA Oncol* (2020) PMID: 32271377
9. Si H, et al. *Clin. Cancer Res.* (2021) PMID: 33355200
10. Leigh NB, et al. *J Thorac Oncol* (2022) PMID: 34800700
11. Li et al., 2020; ASCO Abstract 6511
12. Xiao D, et al. *Oncotarget* (2016) PMID: 27009843
13. Spigel et al., 2016; ASCO Abstract 9017
14. Shim HS, et al. *J Thorac Oncol* (2015) PMID: 26200269
15. Govindan R, et al. *Cell* (2012) PMID: 22980976
16. Ding L, et al. *Nature* (2008) PMID: 18948947
17. Imielinski M, et al. *Cell* (2012) PMID: 22980975
18. Kim Y, et al. *J. Clin. Oncol.* (2014) PMID: 24323028
19. *Nature* (2012) PMID: 22810696
20. Stadler ZK, et al. *J. Clin. Oncol.* (2016) PMID: 27022117
21. Samowitz WS, et al. *Cancer Epidemiol. Biomarkers Prev.* (2001) PMID: 11535541
22. Elsaleh H, et al. *Clin Colorectal Cancer* (2001) PMID: 12445368
23. Brueckl WM, et al. *Anticancer Res.* () PMID: 12820457
24. Guidoboni M, et al. *Am. J. Pathol.* (2001) PMID: 11438476
25. Gryfe R, et al. *N. Engl. J. Med.* (2000) PMID: 10631274
26. Sinicrope FA, et al. *Gastroenterology* (2006) PMID: 16952542
27. Guastadisegni C, et al. *Eur. J. Cancer* (2010) PMID: 20627535
28. Laghi L, et al. *Dig Dis* (2012) PMID: 22722556
29. Mehnert JM, et al. *J. Clin. Invest.* (2016) PMID: 27159395
30. Cancer Genome Atlas Research Network, et al. *Nature* (2013) PMID: 23636398
31. Hussein YR, et al. *Mod. Pathol.* (2015) PMID: 25394778
32. Church DN, et al. *Hum. Mol. Genet.* (2013) PMID: 23528559
33. Cazier JB, et al. *Nat Commun* (2014) PMID: 24777035
34. Pfeifer GP, et al. *Mutat. Res.* (2005) PMID: 15748635
35. Hill VK, et al. *Annu Rev Genomics Hum Genet* (2013) PMID: 23875803
36. Pfeifer GP, et al. *Oncogene* (2002) PMID: 12379884
37. Rizvi NA, et al. *Science* (2015) PMID: 25765070
38. Johnson BE, et al. *Science* (2014) PMID: 24336570
39. Choi S, et al. *Neuro-oncology* (2018) PMID: 29452419
40. Briggs S, et al. *J. Pathol.* (2013) PMID: 23447401
41. Heitzner E, et al. *Curr. Opin. Genet. Dev.* (2014) PMID: 24583393
42. Roberts SA, et al. *Nat. Rev. Cancer* (2014) PMID: 25568919
43. Bronkhorst AJ, et al. *Biomol Detect Quantif* (2019) PMID: 30923679
44. Raja R, et al. *Clin. Cancer Res.* (2018) PMID: 30093454
45. Hrebien S, et al. *Ann. Oncol.* (2019) PMID: 30860573
46. Choudhury AD, et al. *JCI Insight* (2018) PMID: 30385733
47. Goodall J, et al. *Cancer Discov* (2017) PMID: 28450425
48. Goldberg SB, et al. *Clin. Cancer Res.* (2018) PMID: 29330207
49. Bettgowda C, et al. *Sci Transl Med* (2014) PMID: 24553385
50. Lapin M, et al. *J Transl Med* (2018) PMID: 30400802
51. Shulman DS, et al. *Br. J. Cancer* (2018) PMID: 30131550
52. Stover DG, et al. *J. Clin. Oncol.* (2018) PMID: 29298117
53. Hemming ML, et al. *JCO Precis Oncol* (2019) PMID: 30793095
54. Egyud M, et al. *Ann. Thorac. Surg.* (2019) PMID: 31059681
55. Fan G, et al. *PLoS ONE* (2017) PMID: 28187169
56. Vu et al., 2020; DOI: 10.1200/PO.19.00204
57. Li G, et al. *J Gastrointest Oncol* (2019) PMID: 31602320
58. Zhang EW, et al. *Cancer* (2020) PMID: 32757294
59. Butler TM, et al. *Cold Spring Harb Mol Case Stud* (2019) PMID: 30833418
60. Nakano H, et al. *Proc. Natl. Acad. Sci. U.S.A.* (1984) PMID: 6320174
61. Pylyayeva-Gupta Y, et al. *Nat. Rev. Cancer* (2011) PMID: 21993244
62. Yamaguchi T, et al. *Int. J. Oncol.* (2011) PMID: 21523318
63. Watanabe M, et al. *Cancer Sci.* (2013) PMID: 23438367
64. Gilmartin AG, et al. *Clin. Cancer Res.* (2011) PMID: 21245089
65. Yeh JJ, et al. *Mol. Cancer Ther.* (2009) PMID: 19372556
66. Monk BJ, et al. *J Clin Oncol* (2020) PMID: 32822286
67. Farley J, et al. *Lancet Oncol.* (2013) PMID: 23261356
68. Slosberg ED, et al. *Oncotarget* (2018) PMID: 29765547
69. Han C, et al. *Gynecol Oncol Rep* (2018) PMID: 29946554
70. Lyons YA, et al. *Gynecol Oncol Rep* (2014) PMID: 26075998
71. Infante JR, et al. *Lancet Oncol.* (2012) PMID: 22805291
72. Zimmer L, et al. *Clin. Cancer Res.* (2014) PMID: 24947927
73. Bannouna J, et al. *Invest New Drugs* (2011) PMID: 20127139
74. Weekes CD, et al. *Clin. Cancer Res.* (2013) PMID: 23434733
75. Van Laethem JL, et al. *Target Oncol* (2017) PMID: 27975152
76. Infante JR, et al. *Eur. J. Cancer* (2014) PMID: 24915778
77. Van Cutsem E, et al. *Int. J. Cancer* (2018) PMID: 29756206
78. Blumenschein GR, et al. *Ann. Oncol.* (2015) PMID: 25722381
79. Leijen S, et al. *Clin. Cancer Res.* (2012) PMID: 22767668
80. Liu JF, et al. *Gynecol. Oncol.* (2019) PMID: 3118140
81. Spreafico et al., 2014; ASCO Abstract 5506
82. Juric et al., 2014; ASCO Abstract 9051
83. Banerji et al., 2014; ASCO Abstract e13559
84. Shapiro GI, et al. *Invest New Drugs* (2019) PMID: 31020608
85. Guo C, et al. *Lancet Oncol* (2020) PMID: 33128873
86. Krebs et al., 2021; AACR Abstract CT019
87. Shinde et al., 2020; AACR Abstract CT143
88. Lu H, et al. *Mol Cancer Ther* (2019) PMID: 31068384
89. Mainardi S, et al. *Nat Med* (2018) PMID: 29808006
90. Koczywas et al., 2021; AACR Abstract LB001
91. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
92. Hillig RC, et al. *Proc Natl Acad Sci U S A* (2019) PMID: 30683722
93. Hofmann MH, et al. *Cancer Discov* (2021) PMID: 32816843
94. Hofmann et al., 2021; AACR Abstract CT210
95. Gort et al., 2020; ASCO Abstract TPS3651
96. Tate JG, et al. *Nucleic Acids Res.* (2019) PMID: 30371878
97. Lièvre A, et al. *Cancer Res.* (2006) PMID: 16618717
98. De Roock W, et al. *Lancet Oncol.* (2011) PMID: 21163703
99. Huang CW, et al. *BMC Cancer* (2013) PMID: 24330663
100. Kosmidou V, et al. *Hum. Mutat.* (2014) PMID: 24352906
101. Maus MK, et al. *Lung Cancer* (2014) PMID: 24331409
102. Peeters M, et al. *J. Clin. Oncol.* (2013) PMID: 23182985
103. Feldmann G, et al. *J Hepatobiliary Pancreat Surg* (2007) PMID: 17520196
104. Rachakonda PS, et al. *PLoS ONE* (2013) PMID: 23565280
105. Hruban RH, et al. *Am. J. Pathol.* (1993) PMID: 8342602
106. Maitra A, et al. *Best Pract Res Clin Gastroenterol* (2006) PMID: 16549325
107. Löffler H, et al. *Oncotarget* (2016) PMID: 27322425
108. Kahn S, et al. *Anticancer Res.* () PMID: 3310850
109. Akagi K, et al. *Biochem. Biophys. Res. Commun.* (2007) PMID: 17150185
110. Bollag G, et al. *J. Biol. Chem.* (1996) PMID: 8955068
111. Buhrman G, et al. *Proc. Natl. Acad. Sci. U.S.A.* (2010) PMID: 20194776
112. Sci. STKE (2004) PMID: 15367757
113. Edkins S, et al. *Cancer Biol. Ther.* (2006) PMID: 16969076
114. Feig LA, et al. *Mol. Cell. Biol.* (1988) PMID: 3043178
115. Gremer L, et al. *Hum. Mutat.* (2011) PMID: 20949621
116. Janakiraman M, et al. *Cancer Res.* (2010) PMID: 20570890
117. Kim E, et al. *Cancer Discov* (2016) PMID: 27147599
118. Lukman S, et al. *PLoS Comput. Biol.* (2010) PMID: 20838576
119. Naguib A, et al. *J Mol Signal* (2011) PMID: 21371307
120. Prior IA, et al. *Cancer Res.* (2012) PMID: 22589270
121. Privé GG, et al. *Proc. Natl. Acad. Sci. U.S.A.* (1992) PMID: 1565661
122. Scheffzek K, et al. *Science* (1997) PMID: 9219684
123. Scholl C, et al. *Cell* (2009) PMID: 19490892
124. Smith G, et al. *Br. J. Cancer* (2010) PMID: 20147967
125. Tyner JW, et al. *Blood* (2009) PMID: 19075190
126. Valencia A, et al. *Biochemistry* (1991) PMID: 2029511
127. White Y, et al. *Nat Commun* (2016) PMID: 26854029
128. Wiest JS, et al. *Oncogene* (1994) PMID: 8058307
129. Angeles AKJ, et al. *Oncol Lett* (2019) PMID: 31289513
130. Tong JH, et al. *Cancer Biol. Ther.* (2014) PMID: 24642870
131. Loree JM, et al. *Clin Cancer Res* (2021) PMID: 34117033
132. Zehir A, et al. *Nat. Med.* (2017) PMID: 28481359
133. Bailey MH, et al. *Cell* (2018) PMID: 29625053
134. Bolton KL, et al. *Nat Genet* (2020) PMID: 33106634
135. Scheuermann JC, et al. *Nature* (2010) PMID: 20436459
136. Cho YS, et al. *J. Biol. Chem.* (2006) PMID: 16606617
137. Park UH, et al. *J. Biol. Chem.* (2011) PMID: 21047783
138. Inoue D, et al. *J. Clin. Invest.* (2013) PMID: 24216483
139. Abdel-Wahab O, et al. *Cancer Cell* (2012) PMID: 22897849
140. Br. J. Cancer (2013) PMID: 23736028
141. Jaiswal S, et al. *N. Engl. J. Med.* (2014) PMID: 25426837
142. Genovese G, et al. *N. Engl. J. Med.* (2014) PMID: 25426838
143. Xie M, et al. *Nat. Med.* (2014) PMID: 25326804
144. Acuna-Hidalgo R, et al. *Am. J. Hum. Genet.* (2017) PMID: 28669404
145. Severson EA, et al. *Blood* (2018) PMID: 29678827
146. Fuster JJ, et al. *Circ. Res.* (2018) PMID: 29420212
147. Hematology Am Soc Hematol Educ Program (2018) PMID: 30504320
148. Chabon JJ, et al. *Nature* (2020) PMID: 32269342
149. Razavi P, et al. *Nat. Med.* (2019) PMID: 31768066
150. Cerami E, et al. *Cancer Discov* (2012) PMID: 22588877
151. Gao J, et al. *Sci Signal* (2013) PMID: 23550210
152. Trowbridge JJ, et al. *Nat. Genet.* (2011) PMID: 22200773
153. *Prog Mol Biol Transl Sci* (2011) PMID: 21507354
154. Yang J, et al. *Mol Med Rep* () PMID: 21887466
155. Vallböhmer D, et al. *Clin Lung Cancer* (2006) PMID:

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

ORDERED TEST # ORD-1573456-01

APPENDIX
References

- 16870044
156. Daskalos A, et al. Cancer (2011) PMID: 21351083
157. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) PMID: 17890317
158. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) PMID: 22011581
159. Kim MS, et al. APMIS (2013) PMID: 23031157
160. Hirai H, et al. Cancer Biol. Ther. (2010) PMID: 20107315
161. Bridges KA, et al. Clin. Cancer Res. (2011) PMID: 21799033
162. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) PMID: 21389100
163. Osman AA, et al. Mol. Cancer Ther. (2015) PMID: 25504633
164. Xu L, et al. Mol. Cancer Ther. (2002) PMID: 12489850
165. Xu L, et al. Mol. Med. (2001) PMID: 11713371
166. Camp ER, et al. Cancer Gene Ther. (2013) PMID: 23470564
167. Kim SS, et al. Nanomedicine (2015) PMID: 25240597
168. Pirolo KF, et al. Mol. Ther. (2016) PMID: 27357628
169. Leijen S, et al. J. Clin. Oncol. (2016) PMID: 27601554
170. Moore et al., 2019; ASCO Abstract 5513
171. Leijen S, et al. J. Clin. Oncol. (2016) PMID: 27998224
172. Lee J, et al. Cancer Discov (2019) PMID: 31315834
173. Méndez E, et al. Clin. Cancer Res. (2018) PMID: 29535125
174. Seligmann JF, et al. J Clin Oncol (2021) PMID: 34538072
175. Gourley et al., 2016; ASCO Abstract 5571
176. Park H, et al. ESMO Open (2022) PMID: 36084396
177. Kandath C, et al. Nature (2013) PMID: 24132290
178. Wongsurawat VJ, et al. Cancer Epidemiol. Biomarkers Prev. (2006) PMID: 16537709
179. Brosh R, et al. Nat. Rev. Cancer (2009) PMID: 19693097
180. Baker SJ, et al. Science (1989) PMID: 2649981
181. Calcagno DQ, et al. BMC Gastroenterol (2013) PMID: 24053468
182. Alsner J, et al. Acta Oncol (2008) PMID: 18465328
183. Olivier M, et al. Clin. Cancer Res. (2006) PMID: 16489069
184. Végran F, et al. PLoS ONE (2013) PMID: 23359294
185. Wild PJ, et al. EMBO Mol Med (2012) PMID: 22678923
186. Lee EJ, et al. Gynecol. Oncol. (2010) PMID: 20006376
187. Ganci F, et al. Ann. Oncol. (2013) PMID: 24107801
188. Lindenbergh-van der Plas M, et al. Clin. Cancer Res. (2011) PMID: 21467160
189. Peltonen JK, et al. Head Neck Oncol (2011) PMID: 21513535
190. Bringuier PP, et al. Int. J. Cancer (1998) PMID: 9761125
191. Feng C, et al. Sci Rep (2014) PMID: 24500328
192. Dong ZY, et al. Clin. Cancer Res. (2017) PMID: 28039262
193. Russo A, et al. J. Clin. Oncol. (2005) PMID: 16172461
194. Brown CJ, et al. Nat. Rev. Cancer (2009) PMID: 19935675
195. Joerger AC, et al. Annu. Rev. Biochem. (2008) PMID: 18410249
196. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) PMID: 12826609
197. Kamada R, et al. J. Biol. Chem. (2011) PMID: 20978130
198. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) PMID: 28472496
199. Yamada H, et al. Carcinogenesis (2007) PMID: 17690113
200. Landrum MJ, et al. Nucleic Acids Res. (2018) PMID: 29165669
201. Bougeard G, et al. J. Clin. Oncol. (2015) PMID: 26014290
202. Sorrell AD, et al. Mol Diagn Ther (2013) PMID: 23355100
203. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) PMID: 11219776
204. Kleihues P, et al. Am. J. Pathol. (1997) PMID: 9006316
205. Gonzalez KD, et al. J. Clin. Oncol. (2009) PMID: 19204208
206. Lalloo F, et al. Lancet (2003) PMID: 12672316
207. Mandelker D, et al. Ann. Oncol. (2019) PMID: 31050713

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2023 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Julie Tse, M.D. | 02 March 2023
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531